Time Intervals Under the Lens at Sweden's First Diagnostic Center for Primary Care Patients With Nonspecific Symptoms of Cancer. A Comparison With Matched Control Patients.

cancer diagnostic center diagnostic interval nonspecific symptoms primary care time intervals

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 12 05 2020
accepted: 23 10 2020
entrez: 17 12 2020
pubmed: 18 12 2020
medline: 18 12 2020
Statut: epublish

Résumé

Fast-track referral pathways for patients with nonspecific, serious symptoms have been implemented in several countries. Our objective was to analyze time intervals in the diagnostic routes of patients diagnosed with cancer at Sweden's first Diagnostic Center (DC) for nonspecific symptoms and compare with time intervals of matched control patients. Adult patients with nonspecific symptoms that could not be explained by an initial investigation in primary care were eligible for referral to the DC. Patients diagnosed with cancer were matched with patients at another hospital within the same healthcare organization. We aimed for two control patients per DC-patient and matched on tumor type, age and sex. Five time intervals were compared: 1) patient interval (first symptom-primary care contact), 2) primary care interval (first visit-referral to the DC/secondary care), 3) diagnostic interval (first visit-cancer diagnosis), 4) information interval (cancer diagnosis-patient informed) and 5) treatment interval (cancer diagnosis-treatment start). Comparisons between groups and matched cohort analyses were made. Sixty-four patients (22.1%) were diagnosed with cancer at the DC, of which eight were not matchable. Forty-two patients were matched with two controls and 14 were matched with one control. There were no significant differences in patient-, primary care-, or diagnostic intervals between the groups. The information interval was shorter at the DC compared to the control group (difference between matched pairs 7 days, p = 0.001) and the treatment interval was also shorter at the DC with significant differences in the matched analysis (difference between matched pairs 13 days, p = 0.049). The findings remained the same in four sensitivity analyses, made to compensate for differences between the groups. Up to diagnosis, we could not detect significant differences in time intervals between the DC and the control group. However, the shorter information and treatment intervals at the DC should be advantageous for these patients who will get timely access to treatment or palliative care. Due to limitations regarding comparability between the groups, the results must be interpreted with caution and further research is warranted. ClinicalTrials.gov-ID: NCT01709539. Registration-date: October 18, 2012.

Identifiants

pubmed: 33330029
doi: 10.3389/fonc.2020.561379
pmc: PMC7735559
doi:

Banques de données

ClinicalTrials.gov
['NCT01709539']

Types de publication

Journal Article

Langues

eng

Pagination

561379

Informations de copyright

Copyright © 2020 Sundquist, Palmér, Rydén, Sävblom, Ji and Stenman.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Br J Cancer. 2015 Mar 31;112 Suppl 1:S65-9
pubmed: 25734387
BMC Public Health. 2016 Oct 5;16(1):1052
pubmed: 27729048
Br J Cancer. 2009 Dec 3;101 Suppl 2:S125-9
pubmed: 19956156
Br J Cancer. 2015 Mar 31;112 Suppl 1:S41-9
pubmed: 25734388
BMJ Open. 2018 Jan 21;8(1):e018168
pubmed: 29358427
Scand J Prim Health Care. 2016 Jun;34(2):205-12
pubmed: 27189513
Br J Cancer. 2011 Mar 15;104(6):934-40
pubmed: 21364593
Lancet. 2011 Jan 8;377(9760):127-38
pubmed: 21183212
BMJ Open. 2020 Jan 10;10(1):e033008
pubmed: 31924638
Cancer Epidemiol. 2017 Oct;50(Pt A):166-172
pubmed: 28807680
BMC Cancer. 2015 May 20;15:421
pubmed: 25990247
Acta Oncol. 2006;45(2):121-3
pubmed: 16546856
Acta Oncol. 2019 Mar;58(3):296-305
pubmed: 30632871
J Clin Epidemiol. 2012 Jun;65(6):669-78
pubmed: 22459430
Ugeskr Laeger. 2010 Oct 11;172(41):2827-31
pubmed: 20961502
Br J Cancer. 2015 Mar 31;112 Suppl 1:S92-107
pubmed: 25734382
J R Soc Med. 2011 Dec;104(12):510-20
pubmed: 22179294
Eur J Cancer Prev. 2010 Nov;19(6):485-95
pubmed: 20706123
Eur J Cancer. 2013 Jun;49(9):2187-98
pubmed: 23453935
Lancet. 1999 Apr 3;353(9159):1119-26
pubmed: 10209974
Cancer Epidemiol. 2017 Apr;47:48-55
pubmed: 28126583
Lancet. 2002 Mar 16;359(9310):909-19
pubmed: 11918907
Br J Gen Pract. 2011 Aug;61(589):e508-12
pubmed: 21801563
BMC Cancer. 2017 Dec 2;17(1):809
pubmed: 29197366
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Br J Cancer. 2012 Mar 27;106(7):1262-7
pubmed: 22415239
Lancet Oncol. 2020 Jan;21(1):73-79
pubmed: 31704137
Fam Pract. 2013 Apr;30(2):153-60
pubmed: 23097250

Auteurs

Jan Sundquist (J)

Center for Primary Health Care Research, Skåne Regional Council, Lund University, Malmö, Sweden.
Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Center for Community-based Healthcare Research and Education (CoHRE), Department of Functional Pathology, Shimane University, Shimane, Japan.

Karolina Palmér (K)

Center for Primary Health Care Research, Skåne Regional Council, Lund University, Malmö, Sweden.

Stefan Rydén (S)

Regional Cancer Centre South, Skåne Regional Council, Kristianstad, Sweden.

Charlotta Sävblom (C)

Regional Cancer Centre Stockholm Gotland, Stockholm Regional Council, Stockholm, Sweden.

Jianguang Ji (J)

Center for Primary Health Care Research, Skåne Regional Council, Lund University, Malmö, Sweden.

Emelie Stenman (E)

Center for Primary Health Care Research, Skåne Regional Council, Lund University, Malmö, Sweden.

Classifications MeSH